ES2092696T3 - Metodos y composiciones relacionadas con antigenos utiles de moraxella catarrhalis. - Google Patents

Metodos y composiciones relacionadas con antigenos utiles de moraxella catarrhalis.

Info

Publication number
ES2092696T3
ES2092696T3 ES92918273T ES92918273T ES2092696T3 ES 2092696 T3 ES2092696 T3 ES 2092696T3 ES 92918273 T ES92918273 T ES 92918273T ES 92918273 T ES92918273 T ES 92918273T ES 2092696 T3 ES2092696 T3 ES 2092696T3
Authority
ES
Spain
Prior art keywords
omps
proteins
moraxella catarrhalis
methods
variants
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES92918273T
Other languages
English (en)
Inventor
Eric J Hansen
Merja Helminen
Isobel Maciver
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Texas System
University of Texas at Austin
Original Assignee
University of Texas System
University of Texas at Austin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Texas System, University of Texas at Austin filed Critical University of Texas System
Application granted granted Critical
Publication of ES2092696T3 publication Critical patent/ES2092696T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Gram-negative bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/21—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pseudomonadaceae (F)
    • C07K14/212—Moraxellaceae, e.g. Acinetobacter, Moraxella, Oligella, Psychrobacter
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Gram-negative bacteria
    • C07K16/1217—Neisseriaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

LA PRESENTE INVENCION SE REFIERE A PROTEINAS ANTIGENICAS SELECCIONADAS OBTENIDAS A PARTIR DE MEMBRANAS EXTERIORES DE MORAXELLA CATARRHALIS, QUE SE HA DESCUBIERTO TIENEN UNA VARIEDAD DE PROPIEDADES UTILES. ESTAS PROTEINAS, DENOMINADAS OMPS ("PROTEINAS DE MEMBRANA EXTERIOR"), QUE CARACTERIZAN PORQUE TIENEN UNOS PESOS MOLECULARES DE 30 KD APROXIMADAMENTE, 80 KD Y ENTRE 200 APROXIMADAMENTE Y 700 KD, RESPECTIVAMENTE. LOS ESTUDIOS PRESENTADOS AQUI DENTRO DEMUESTRAN QUE LOS ANTICUERPOS MONOCLONALES DIRIGIDOS CONTRA ESTAS PROTEINAS CONFIEREN UN EFECTO PROTECTOR CONTRA LA INFECCION PROVOCADA POR ORGANISMOS DE MORAXELLA CATARRHALIS A ANIMALES TOMADOS COMO MODELO, LO QUE DEMUESTRA LA UTILIDAD POTENCIAL DE TALES ANTICUERPOS PARA CONFERIR UNA INMUNIDAD PASIVA ASI COMO LA UTILIDAD POTENCIAL DE ESTAS OMPS, O VARIANTES DE LAS MISMAS, PARA LA PREPARACION DE VACUNAS. TAMBIEN SE PRESENTAN SEGMENTOS DE ADN QUE CODIFICAN ESTAS OMPS, LOS METODOS PARA LA PREPARACION DE LOS ANTIGENOS, O VARIANTES, MEDIANTE LA APLICACION DE TECNICAS DEL ADN RECOMBINANTE, ASI COMO METODOS DE DIAGNOSTICO Y ASPECTOS DE LA INVENCION.
ES92918273T 1991-08-15 1992-08-14 Metodos y composiciones relacionadas con antigenos utiles de moraxella catarrhalis. Expired - Lifetime ES2092696T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/745,591 US5552146A (en) 1991-08-15 1991-08-15 Methods and compositions relating to useful antigens of Moraxella catarrhalis

Publications (1)

Publication Number Publication Date
ES2092696T3 true ES2092696T3 (es) 1996-12-01

Family

ID=24997358

Family Applications (1)

Application Number Title Priority Date Filing Date
ES92918273T Expired - Lifetime ES2092696T3 (es) 1991-08-15 1992-08-14 Metodos y composiciones relacionadas con antigenos utiles de moraxella catarrhalis.

Country Status (14)

Country Link
US (3) US5552146A (es)
EP (1) EP0612250B1 (es)
JP (1) JP3499868B2 (es)
KR (1) KR100271888B1 (es)
AT (1) ATE140627T1 (es)
AU (1) AU666329B2 (es)
CA (1) CA2115565C (es)
DE (1) DE69212495T2 (es)
DK (1) DK0612250T3 (es)
ES (1) ES2092696T3 (es)
FI (1) FI106844B (es)
GR (1) GR3021423T3 (es)
NO (2) NO308413B1 (es)
WO (1) WO1993003761A1 (es)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2693654B1 (fr) * 1992-07-20 1994-08-26 Oreal Médicament, notamment immunomodulateur, contenant des enveloppes ou fractions d'enveloppes de bactéries filamenteuses non photosynthétiques et non fructifiantes, et sa préparation.
DK0624376T3 (da) 1993-05-13 2000-07-24 American Cyanamid Co Fremstilling og anvendelse af LOS-udtømte ydre membranproteiner af gram-negative cocci
US5712118A (en) * 1993-09-29 1998-01-27 Research Foundation Of State University Of New York Vaccine for branhamella catarrhalis
US5607846A (en) * 1994-05-17 1997-03-04 Research Foundation Of State University Of New York Vaccine for moraxella catarrhalis
US6121427A (en) * 1994-10-24 2000-09-19 Connaught Laboratories Limited Major outer membrane protein CD of branhamella
US6335018B1 (en) * 1995-05-01 2002-01-01 Aventis Pasteur Limited High molecular weight major outer membrane protein of moraxella
US6440425B1 (en) 1995-05-01 2002-08-27 Aventis Pasteur Limited High molecular weight major outer membrane protein of moraxella
US6290970B1 (en) * 1995-10-11 2001-09-18 Aventis Pasteur Limited Transferrin receptor protein of Moraxella
KR100500000B1 (ko) * 1996-05-03 2005-12-12 안텍스 바이오로직스 인코퍼레이션 모락셀라카타르할리스외측막단백질-16폴리펩티드,이의유전자서열및이의용도
US7341727B1 (en) * 1996-05-03 2008-03-11 Emergent Product Development Gaithersburg Inc. M. catarrhalis outer membrane protein-106 polypeptide, methods of eliciting an immune response comprising same
US6004562A (en) * 1996-08-16 1999-12-21 The Research Foundation Of The State University Of New York Outer membrane protein B1 of Moraxella catarrhalis
US6558677B2 (en) * 1996-10-15 2003-05-06 Wendell D. Zollinger Vaccine against gram negative bacteria
KR100615109B1 (ko) 1996-12-20 2006-08-22 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 모렉셀라 카타르할리스의 ｕｓｐａ1, ｕｓｐａ2 항원
GB9810084D0 (en) 1998-05-11 1998-07-08 Cortecs Uk Ltd Proteins
US6627728B1 (en) 1998-05-12 2003-09-30 Smithkline Beecham Biologicals S.A. Compounds from moraxella catarrhalis
GB9810285D0 (en) 1998-05-13 1998-07-15 Smithkline Beecham Biolog Novel compounds
GB9812440D0 (en) * 1998-06-09 1998-08-05 Smithkline Beecham Biolog Novel compounds
ES2275499T3 (es) 1999-03-19 2007-06-16 Glaxosmithkline Biologicals S.A. Vacuna contra streptococcus pneumoniae.
GB9914945D0 (en) * 1999-06-25 1999-08-25 Smithkline Beecham Biolog Novel compounds
GB9921691D0 (en) * 1999-09-14 1999-11-17 Smithkline Beecham Sa Novel compounds
GB0022742D0 (en) 2000-09-15 2000-11-01 Smithkline Beecham Biolog Vaccine
GB0103171D0 (en) 2001-02-08 2001-03-28 Smithkline Beecham Biolog Vaccine composition
EP1524991A1 (en) 2002-08-02 2005-04-27 GlaxoSmithKline Biologicals S.A. Vaccine composition comprising transferrin binding protein and hsf from gram negative bacteria
GB0220194D0 (en) 2002-08-30 2002-10-09 Chiron Spa Improved vesicles
GB0424092D0 (en) 2004-10-29 2004-12-01 Chiron Srl Immunogenic bacterial vesicles with outer membrane proteins
CA2604363C (en) 2005-04-08 2015-06-16 Wyeth Multivalent pneumococcal polysaccharide-protein conjugate composition
US7709001B2 (en) 2005-04-08 2010-05-04 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
TWI457133B (zh) 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
PL1973564T3 (pl) 2005-12-22 2017-04-28 Glaxosmithkline Biologicals S.A. Szczepionki zawierające koniugaty polisacharydu otoczkowego streptococcus pneumoniae
GB0607088D0 (en) 2006-04-07 2006-05-17 Glaxosmithkline Biolog Sa Vaccine
AU2007206114B2 (en) 2006-01-17 2013-01-24 Arne Forsgren A novel surface exposed Haemophilus influenzae protein (protein E; pE)
SI2167121T1 (sl) 2007-06-26 2015-12-31 Glaxosmithkline Biologicals S.A. Cepivo, ki obsega kapsularne polisaharidne konjugate Streptococcusa pneumoniae
JP5723768B2 (ja) 2008-05-30 2015-05-27 ザ ユナイテッド ステイツ オブ アメリカ， アズ レプレゼンテッド バイ ザ セクレタリー オブ ジ アーミー， オン ビハーフ オブ ウォルター リード アーミー インスティチュート オブ リサーチ 髄膜炎菌性多価未変性外膜小胞ワクチン、その作製方法およびその使用
GB201003924D0 (en) 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Immunogenic composition
GB201003922D0 (en) 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Conjugation process
EP2544714A1 (en) 2010-03-10 2013-01-16 GlaxoSmithKline Biologicals S.A. Vaccine composition
GB201103836D0 (en) 2011-03-07 2011-04-20 Glaxosmithkline Biolog Sa Conjugation process
GB201518684D0 (en) 2015-10-21 2015-12-02 Glaxosmithkline Biolog Sa Vaccine
GB201621686D0 (en) 2016-12-20 2017-02-01 Glaxosmithkline Biologicals Sa Novel methods for inducing an immune response
CA3063954A1 (en) 2017-05-30 2018-12-06 Glaxosmithline Biologicals S.A. Methods for manufacturing an adjuvant
BR112020010790A2 (pt) 2017-12-01 2020-11-10 Glaxosmithkline Biologicals S.A. purificação da saponina
US20210283238A1 (en) 2018-08-07 2021-09-16 Glaxosmithkline Biologicals Sa Novel processes and vaccines
WO2020109365A1 (en) 2018-11-29 2020-06-04 Glaxosmithkline Biologicals Sa Methods for manufacturing an adjuvant
JP7640473B2 (ja) 2019-06-05 2025-03-05 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム サポニン精製
GB202205833D0 (en) 2022-04-21 2022-06-08 Glaxosmithkline Biologicals Sa Bacteriophage
WO2024017827A1 (en) 2022-07-19 2024-01-25 Glaxosmithkline Biologicals Sa Continuous process for vaccine production

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5030556A (en) * 1989-03-30 1991-07-09 Danielle Beaulieu Species-specific DNNA probe for the detection of Branhamella catarrhalis

Also Published As

Publication number Publication date
FI940681L (fi) 1994-04-07
KR100271888B1 (ko) 2000-11-15
ATE140627T1 (de) 1996-08-15
FI940681A0 (fi) 1994-02-14
JPH07501210A (ja) 1995-02-09
NO20002413D0 (no) 2000-05-09
FI106844B (fi) 2001-04-30
DK0612250T3 (da) 1996-11-25
US5759813A (en) 1998-06-02
EP0612250A1 (en) 1994-08-31
EP0612250B1 (en) 1996-07-24
NO940502D0 (no) 1994-02-14
CA2115565C (en) 2007-08-07
JP3499868B2 (ja) 2004-02-23
WO1993003761A1 (en) 1993-03-04
DE69212495D1 (de) 1996-08-29
AU666329B2 (en) 1996-02-08
CA2115565A1 (en) 1993-03-04
NO308413B1 (no) 2000-09-11
NO940502L (no) 1994-03-28
NO20002413L (no) 2000-05-09
US5552146A (en) 1996-09-03
GR3021423T3 (en) 1997-01-31
DE69212495T2 (de) 1997-03-06
US5599693A (en) 1997-02-04
AU2487892A (en) 1993-03-16

Similar Documents

Publication Publication Date Title
ES2092696T3 (es) Metodos y composiciones relacionadas con antigenos utiles de moraxella catarrhalis.
Montaraz et al. Identification of a 68-kilodalton protective protein antigen from Bordetella bronchiseptica
US5648081A (en) Actinobacillus pleuropneumoniae subunit vaccine
EP0090581A3 (en) Small peptides with the specificity of foot and mouth disease viral antigens
FI903154A0 (fi) Kimeriska glykoproteiner innehaollande immunogeniska segment av glykoproteiner av maenniskans respiratory syncytial-virus.
EP0793717A4 (en) ORAL IMMUNIZATION BY USING TRANSGENIC PLANTS
PT90727B (pt) Processo para a preparacao de uma proteina possuindo um ou mais determinantes imuno-reactivos e/ou antigenicos de um antigenio de superficie eimeria e de vacinas contra a coccidiose que a contem
BR9712970A (pt) Método para produção de vacina para proteção contra virus sincitial respiratório, mistura de proteìna de fusão purificada, composição imunogênica
NO913428D0 (no) Humant intra-acrosomalt sperma-antigen for anvendelse i en befruktningshindrende vaksine.
Jarrett et al. Antibody response and virus survival in cats vaccinated against feline leukaemia
ATE508139T1 (de) Synthetische peptid-hiv-vakzine: das cbd-epitop als effizientes immunogen zur induktion hiv- neutralisierender antikörper
GB2202851A (en) Proteinaceous material from, and vaccine against, pasteurella
DK482788D0 (da) Vacciner mod og diagnostiske bestemmelser af haemophilus influenzae
FI120149B (fi) Ei tyypittävissä olevan Haemophilus influenzaen puhdistettu P5 proteiini rokotteena ei tyypittävissä olevalle Haemophilus influenzae -kannalle
RU2020109137A (ru) Вакцина для защиты от streptococcus suis
Glisson et al. In vivo antigen expression by Pasteurella multocida
ES2316576T3 (es) Nueva proteina de union a inmunoglobulina d expuesta sobre la superficie procedente de moraxella catarrhalis.
FR2646776B1 (fr) Utilisation de preparations vaccinantes a base d'adenyl cyclase ou de bacteries les produisant en tant qu'antigenes protecteurs contre les effets des bordetella
EP0400107A1 (en) Swine dysentery subunit vaccine and method
PT84976B (pt) Metodo para a producao de antigenios de virus de leucemia felina contendo polipeptideos recombinantes
BR9814556A (pt) Cepas isoladas de staphylococcus aureus e vacinas fabricadas a partir das mesmas
JPH03163028A (ja) うし流行熱抗原およびそのワクチン
US1122379A (en) Process for the preparation of a vaccine.
ATE103817T1 (de) Gegen pseudomonas aeruginosa-infektionen wirksame praeparationen sowie immunglobulin-g-haeltige, gegen bakterium pseudomonas aeruginosa wirksame praeparationen.
Mohamed Purification and Immunological Evaluation of Protective Antigens of Outer Membrane Origin of Pasteurella Multocida Type 6: B

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 612250

Country of ref document: ES